P

Poolbeg Pharma PLC
LSE:POLB

Watchlist Manager
Poolbeg Pharma PLC
LSE:POLB
Watchlist
Price: 7.105 GBX -0.63% Market Closed
Market Cap: 35.5m GBX
Have any thoughts about
Poolbeg Pharma PLC?
Write Note

Poolbeg Pharma PLC
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Poolbeg Pharma PLC
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
P
Poolbeg Pharma PLC
LSE:POLB
Total Current Assets
ÂŁ13.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Total Current Assets
ÂŁ16.8B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
2%
AstraZeneca PLC
LSE:AZN
Total Current Assets
$25.4B
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
5%
Verona Pharma PLC
NASDAQ:VRNA
Total Current Assets
$364.3m
CAGR 3-Years
25%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Total Current Assets
$2.3B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
8%
Dechra Pharmaceuticals PLC
LSE:DPH
Total Current Assets
ÂŁ467.9m
CAGR 3-Years
1%
CAGR 5-Years
14%
CAGR 10-Years
10%
No Stocks Found

Poolbeg Pharma PLC
Glance View

Market Cap
35.5m GBX
Industry
Pharmaceuticals

Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.

POLB Intrinsic Value
2.434 GBX
Overvaluation 66%
Intrinsic Value
Price
P

See Also

What is Poolbeg Pharma PLC's Total Current Assets?
Total Current Assets
13.5m GBP

Based on the financial report for Dec 31, 2023, Poolbeg Pharma PLC's Total Current Assets amounts to 13.5m GBP.

What is Poolbeg Pharma PLC's Total Current Assets growth rate?
Total Current Assets CAGR 1Y
-21%

Over the last year, the Total Current Assets growth was -21%.

Back to Top